Cost-effectiveness of populationwide educational approaches to reduce serum cholesterol levels

Circulation

Volumn 95, Issue 1, 1997, Pages 24-30

  Tosteson, Anna N A ^a   Weinstein, Milton C ^b   Hunink, Maria G M ^b,c   Mittleman, Murray A ^d   Williams, Lawrence W ^b   Goldman, Paula A ^b   Goldman, Lee ^e  

^a DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cholesterol; coronary disease; cost benefit analysis; prevention

Indexed keywords

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; HEALTH EDUCATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; PATIENT EDUCATION; PRIORITY JOURNAL; RISK MANAGEMENT;

EID: 0031014387     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.1.24     Document Type: Article

References (13)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
2. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36-69.
3. Wilson PWF, Christiansen JC, Anderson KM, Kannel WB. Impact of national guidelines for cholesterol risk screening: the Framingham Offspring Study. JAMA. 1989;262:41-44.
4. Sempos C, Fulwood R, Haines C, Carroll M, Anda R, Williamson DF, Remington P, Cleeman J. The prevalence of high blood cholesterol levels among adults in the United States. JAMA. 1989;262:45-52.
5. Goldman L, Weinstein MC, Williams LW. Relative impact of targeted versus populationwide cholesterol interventions on the incidence of coronary heart disease. Circulation. 1989;80:254-260.
6. Kottke TE, Puska P, Salonen JT, Tuomilehto J, Nissinen A. Projected effects of high-risk versus population-based preventions strategies in coronary heart disease. Am J Epidemiol. 1985;121:697-704.
7. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA. 1991;265:1145-1151.
8. Martens LL, Rutten FFH, Erkelens DW, Ascoop CAPL. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels. Am J Cardiol. 1990;65:27F-30F.
9. Schulman K, Kinosian B, Jacobson T, Glick H, Eisenberg JM. Reducing high blood cholesterol with drugs: cost-effectiveness of pharmacologic management. JAMA. 1990;264:3025-3033.
10. Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: estimating the benefits of increasing HDL-C. JAMA. 1995;273:1032-1038.
11. Pedersen TR, Kjekshus J, Berg K, Olsson AG, Wilhelmsen L, Wedel H, Pyörälä K, Miettinen T, Haghfelt T, Færgeman O, Thorgeirsson G, Jönsson B, Schwartz JS, for the Scandinavian Simvistatin Survival Group. Cholesterol lowering and the use of health care resources: results of the Scandinavian Simvistatin Survival Study. Circulation. 1996;93:1796-1802.
12. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DS, Kinosian B, Weinstein MC. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-1968.
13. Kristiansen IS, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worth while? Br Med J. 1991;302:1119-1122.